Senti Biosciences, Inc.·4

Mar 11, 4:01 PM ET

Rajangam Kanya 4

Research Summary

AI-generated summary

Updated

Senti Biosciences President Kanya Withholds 10,757 Shares for Taxes

What Happened

  • Rajangam Kanya, President & Chief Medical and Development Officer of Senti Biosciences (SNTI), had 10,757 shares withheld on 2026-03-09 to satisfy tax withholding obligations related to the net settlement of time‑based restricted stock units (RSUs). The filing reports a disposal under code F at $0.00 per share (no cash proceeds reported).

Key Details

  • Transaction date: 2026-03-09; Form 4 filed: 2026-03-11 (filed timely).
  • Reported shares withheld/disposed: 10,757 shares at $0.00 (reported value $0).
  • Shares owned after transaction: not specified in the provided filing details.
  • Footnote: Issuer withheld the shares to satisfy income tax withholding for net-settled RSUs; this was not an open‑market sale.
  • Transaction code: F (payment of exercise price or tax liability via share withholding).

Context

  • This is a routine tax-withholding transaction following an RSU vesting and does not indicate an open-market sale or a change in Kanya’s decision to sell shares. Such net‑settlement withholdings reduce the insider’s share count but are commonly used by companies to cover taxes on awarded equity and are not typically interpreted as a directional signal about the insider’s view of the company.